HC Wainwright Rates Faeth Therapeutics (FTH) buy

HC Wainwright maintains a buy rating for FTH with a $60 price target, a 236.70% upside from the current price.

By TradeTexts Research Desk · Published Jun 22, 2026, 8:01 AM EDT · Updated Jun 22, 2026, 9:06 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Faeth Therapeutics, Inc. ($FTH) "buy" with a $60 price target on June 22, 2026.

Since the rating, $FTH is up 0.1% after 1 week, up 23.6% after 1 month and down 18.9% to date (from the $23.19 close on Jun 22, 2026).

FTH Faeth Therapeutics, Inc.

$18.80 +95.02% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright reaffirms its buy rating for FTH, setting a $60 price target on June 22, 2026.
HC Wainwright's $60 price target implies 236.70% upside from Faeth Therapeutics, Inc.'s ($FTH) current $17.82 share price.
FTH shares traded at $17.82 on Monday, reflecting the market's current valuation.
Analyst Patrick R. Trucchio from HC Wainwright initiated this rating, highlighting confidence in FTH's potential.

Get $FTH trade alerts by text

We text you when insiders, Congress or big funds trade $FTH. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Faeth Therapeutics, Inc. alert may contain errors. Disclosures

On June 22, 2026, HC Wainwright reiterated its buy rating for FTH, setting a price target of $60. Analyst Patrick R. Trucchio expressed continued confidence in the company's potential with this reaffirmation.

Analyst rating track record

HC Wainwright & Co. vs. the S&P 500

YTD return +49.04% hypothetical

All-time return +148.12% S&P 500 +29.05%

vs. S&P 500 +119.07% ahead of the index

Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.

Analysts Set New Price Targets

On June 22, 2026, HC Wainwright & Co. initiated coverage on FTH with a buy rating and a $60 price target. This move by analyst Patrick R. Trucchio suggests a positive outlook for the company, as the target is significantly higher than the current trading price.

Faeth Therapeutics, Inc. Stock Down 48.3%

Shares of FTH traded at $17.82 on Monday. The stock's current valuation in the market reflects the ongoing analysis and expectations of future performance. The reiterated buy rating and $60 price target indicate that analysts see potential growth opportunities ahead.

12-month forecast

$FTH price target

Faeth Therapeutics, Inc. daily closes and this analyst's $60 target. Not advice.

Bottom Line

HC Wainwright's reaffirmation of a buy rating for FTH, along with a $60 target, indicates confidence in the company's future prospects. Investors often track such ratings to gauge market sentiment and potential growth. It's important to remember that analyst ratings are forward-looking and based on current assessments.